Rational combination strategies to enhance venetoclax activity and overcome resistance in hematologic malignancies

References

• Brinkmann K, Kashkar H. Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies? Cell Death Dis. 2014;5:e1098.
   PubMed Web of Science ®Google Scholar
• Reed JC. Apoptosis-targeted therapies for cancer. Cancer Cell. 2003;3:17–22.
   PubMed Web of Science ®Google Scholar
• Czabotar PE, Lessene G, Strasser A, et al. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014;15:49–63.
   PubMed Web of Science ®Google Scholar
• Chipuk JE, Fisher JC, Dillon CP, et al. Mechanism of apoptosis induction by inhibition of the anti-apoptotic BCL-2 proteins. Proc Natl Acad Sci USA. 2008;105:20327–20332.
   PubMed Web of Science ®Google Scholar
• Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science. 2004;305:626–629.
   PubMed Web of Science ®Google Scholar
• Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9:47–59.
   PubMed Web of Science ®Google Scholar
• Morales AA, Kurtoglu M, Matulis SM, et al. Distribution of Bim determines Mcl-1 dependence or co-dependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells. Blood. 2011;118:1329–1339.
   PubMed Web of Science ®Google Scholar
• Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006;25:4798–4811.
   PubMed Web of Science ®Google Scholar
• Walczak H. Death receptor-ligand systems in cancer, cell death, and inflammation. Cold Spring Harb Perspect Biol. 2013;5:a008698.
   PubMed Web of Science ®Google Scholar
• Pennarun B, Meijer A, de Vries EG, et al. Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer. Biochim Biophys Acta. 2010;1805:123–140.
   PubMed Web of Science ®Google Scholar
• Imre G, Larisch S, Rajalingam K. Ripoptosome: a novel IAP-regulated cell death-signalling platform. J Mol Cell Biol. 2011;3:324–326.
   PubMed Web of Science ®Google Scholar
• Oancea M, Mani A, Hussein MA, et al. Apoptosis of multiple myeloma. Int J Hematol. 2004;80:224–231.
   PubMed Web of Science ®Google Scholar
• Green DR. At the gates of death. Cancer Cell. 2006;9:328–330.
   PubMed Web of Science ®Google Scholar
• Chipuk JE, Moldoveanu T, Llambi F, et al. The BCL-2 family reunion. Mol Cell. 2010;37:299–310.
   PubMed Web of Science ®Google Scholar
• Willis SN, Chen L, Dewson G, et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 2005;19:1294–1305.
   PubMed Web of Science ®Google Scholar
• She QB, Solit DB, Ye Q, et al. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell. 2005;8:287–297.
   PubMed Web of Science ®Google Scholar
• Gomez-Bougie P, Wuilleme-Toumi S, Menoret E, et al. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res. 2007;67:5418–5424.
   PubMed Web of Science ®Google Scholar
• MacCallum DE, Melville J, Frame S, et al. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res. 2005;65:5399–5407.
   PubMed Web of Science ®Google Scholar
• Yoshimoto G, Miyamoto T, Jabbarzadeh-Tabrizi S, et al. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood. 2009;114:5034–5043.
   PubMed Web of Science ®Google Scholar
• Gojo I, Zhang B, Fenton RG. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res. 2002;8:3527–3538.
   PubMed Web of Science ®Google Scholar
• Kasper S, Breitenbuecher F, Heidel F, et al. Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies. Blood Cancer J. 2012;2:e60.
   PubMed Web of Science ®Google Scholar
• Kline MP, Rajkumar SV, Timm MM, et al. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia. 2007;21:1549–1560.
   PubMed Web of Science ®Google Scholar
• Pan R, Hogdal LJ, Benito JM, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014;4:362–375.
   PubMed Web of Science ®Google Scholar
• Bodet L, Gomez-Bougie P, Touzeau C, et al. ABT-737 is highly effective against molecular subgroups of multiple myeloma. Blood. 2011;118:3901–3910.
   PubMed Web of Science ®Google Scholar
• Chen S, Zhang Y, Zhou L, et al. A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis. Blood. 2014;124:2687–2697.
   PubMed Web of Science ®Google Scholar
• Inoue S, Riley J, Gant TW, et al. Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa. Leukemia. 2007;21:1773–1782.
   PubMed Web of Science ®Google Scholar
• Touzeau C, Ryan J, Guerriero J, et al. BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. Leukemia. 2016;30:761–764.
   PubMed Web of Science ®Google Scholar
• Punnoose E, Leverson JD, Peale F, et al. Expression profile of BCL-2, BCL-XL and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models. Mol Cancer Ther. 2016;15:1132–1144.
   PubMed Web of Science ®Google Scholar
• Bose P, Gandhi V, Konopleva M. Pathways and mechanisms of venetoclax resistance. Leuk Lymphoma 2017;58:2026–2039.
   PubMed Web of Science ®Google Scholar
• Certo M, Moore VG, Nishino M, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006;9:351–365.
   PubMed Web of Science ®Google Scholar
• Deng J, Carlson N, Takeyama K, et al. profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell. 2007;12:171–185.
   PubMed Web of Science ®Google Scholar
• Anderson MA, Huang D, Roberts A. Targeting BCL2 for the treatment of lymphoid malignancies. Semin Hematol. 2014;51:219–227.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:311–322.
   PubMed Web of Science ®Google Scholar
• Deeks ED. Venetoclax: first global approval. Drugs. 2016;76:979–987.
   PubMed Web of Science ®Google Scholar
• Itchaki G, Brown JR. The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia. Ther Adv Hematol. 2016;7:270–287.
   PubMed Web of Science ®Google Scholar
• Cervantes-Gomez F, Lamothe B, Woyach JA, et al. Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia. Clin Cancer Res. 2015;21:3705–3715.
   PubMed Web of Science ®Google Scholar
• Deng J, Isik E, Fernandes SM, et al. Bruton’s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Leukemia. Forthcoming. [cited 2017 Feb 14]. DOI:10.1038/leu.2017.32
   Web of Science ®Google Scholar
• Chiron D, Dousset C, Brosseau C, et al. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma. Oncotarget. 2015;6:8750–8759.
   PubMed Web of Science ®Google Scholar
• Aw A, Brown JR. The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia. Leuk Lymphoma. 2017;58:2287–2297.
   PubMed Web of Science ®Google Scholar
• Jones JA, Woyach J, Awan FT, et al. Phase 1b results of a phase 1b/2 study of obinutuzmab, ibrutinib, and venetoclax in relapsed/refractory chronic lymphocytic leukemia (CLL). Blood. 2016;128:639.
   Web of Science ®Google Scholar
• Patel VM, Balakrishnan K, Douglas M, et al. Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199). Leukemia. Forthcoming. [cited 2017 Feb 3]. DOI:10.1038/leu.2016.382
   Web of Science ®Google Scholar
• Bojarczuk K, Sasi BK, Gobessi S, et al. BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199. Blood. 2016;127:3192–3201.
   PubMed Web of Science ®Google Scholar
• Oppermann S, Ylanko J, Shi Y, et al. High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells. Blood. 2016;128:934–947.
   PubMed Web of Science ®Google Scholar
• Choudhary GS, Al-Harbi S, Mazumder S, et al. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. Cell Death Dis. 2015;6:e1593.
   PubMed Web of Science ®Google Scholar
• Rahmani M, Aust MM, Attkisson E, et al. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a. Cancer Res. 2013;73:1340–1351.
   PubMed Web of Science ®Google Scholar
• Li L, Pongtornpipat P, Tiutan T, et al. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1. Leukemia. 2015;29:1702–1712.
   PubMed Web of Science ®Google Scholar
• Bui MH, Lin X, Albert DH, et al. Preclinical characterization of BET family bromodomain inhibitor ABBV-075 suggests combination therapeutic strategies. Cancer Res. 2017;77:2976–2989.
   PubMed Web of Science ®Google Scholar
• Peirs S, Frismantas V, Matthijssens F, et al. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia. Leukemia. Forthcoming. [cited 2017 Feb 3]. DOI:10.1038/leu.2017.10
   Web of Science ®Google Scholar
• Chiron D, Bellanger C, Papin A, et al. Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma. Blood. 2016;128:2808–2818.
   PubMed Web of Science ®Google Scholar
• Bodo J, Zhao X, Durkin L, et al. Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells. Oncotarget. 2016;7:70000–70010.
   PubMed Web of Science ®Google Scholar
• Thijssen R, Slinger E, Weller K, et al. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. Haematologica. 2015;100:e302–e306.
   PubMed Web of Science ®Google Scholar
• Montraveta A, Xargay-Torrent S, Rosich L, et al. Bcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199. Oncotarget. 2015;6:21159–21172.
   PubMed Web of Science ®Google Scholar
• Phillips DC, Xiao Y, Lam LT, et al. Loss in MCL-1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199). Blood Cancer J. 2015;5:e368.
   PubMed Web of Science ®Google Scholar
• Klanova M, Andera L, Brazina J, et al. Targeting of BCL2 family proteins with ABT-199 and homoharringtonine reveals BCL2- and MCL1-dependent subgroups of diffuse large B-cell lymphoma. Clin Cancer Res. 2016;22:1138–1149.
   PubMed Web of Science ®Google Scholar
• Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6:1106–1117.
   PubMed Web of Science ®Google Scholar
• Bogenberger JM, Kornblau SM, Pierceall WE, et al. BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia. 2014;28:1657–1665.
   PubMed Web of Science ®Google Scholar
• DiNardo C, Pollyea D, Pratz K, et al. A phase 1b study of venetoclax (ABT-199/GDC-0199) in combination with decitabine or azacitidine in treatment-naive patients with acute myelogenous leukemia who are ≥65 years and not eligible for standard induction therapy. Blood (Abstract). 2015;126:327.
   Web of Science ®Google Scholar
• Chan SM, Thomas D, Corces-Zimmerman MR, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 2015;21:178–184.
   PubMed Web of Science ®Google Scholar
• Jacque N, Ronchetti AM, Larrue C, et al. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition. Blood. 2015;126:1346–1356.
   PubMed Web of Science ®Google Scholar
• Knorr KL, Schneider PA, Meng XW, et al. MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors. Cell Death Differ. 2015;22:2133–2142.
   PubMed Web of Science ®Google Scholar
• Ruvolo PP, Ruvolo VR, Benton CB, et al. Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells. Biochim Biophys Acta. 2016;1863:562–571.
   PubMed Web of Science ®Google Scholar
• Lehmann C, Friess T, Birzele F, et al. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models. J Hematol Oncol. 2016;9:50.
   PubMed Web of Science ®Google Scholar
• Qi B, Hardwick JM. A Bcl-xL timer sets platelet life span. Cell. 2007;128:1035–1036.
   PubMed Web of Science ®Google Scholar
• Touzeau C, Dousset C, Le GS, et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia. 2014;28:210–212.
   PubMed Web of Science ®Google Scholar
• Bajpai R, Matulis SM, Wei C, et al. Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax. Oncogene. 2016;35:3955–3964.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Schlossman RL, Alsina M, et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood. 2013;122:2331–2337.
   PubMed Web of Science ®Google Scholar
• San-Miguel JF, Richardson PG, Gunther A, et al. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol. 2013;31:3696–3703.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Tan J, Zhuang L, et al. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci USA. 2005;102:16090–16095.
   PubMed Web of Science ®Google Scholar
• Chen S, Dai Y, Pei XY, et al. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies. Cancer Res. 2012;72:4225–4237.
   PubMed Web of Science ®Google Scholar
• Chen S, Zhou L, Zhang Y, et al. Targeting SQSTM1/p62 induces cargo loading failure and converts autophagy to apoptosis via NBK/Bik. Mol.Cell Biol. 2014 ;34:3435–3415.
   PubMed Web of Science ®Google Scholar
• Yuan BZ, Chapman J, Reynolds SH. Proteasome inhibitors induce apoptosis in human lung cancer cells through a positive feedback mechanism and the subsequent Mcl-1 protein cleavage. Oncogene. 2009;28:3775–3786.
   PubMed Web of Science ®Google Scholar
• Chauhan D, Velankar M, Brahmandam M, et al. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene. 2007;26:2374–2380.
   PubMed Web of Science ®Google Scholar
• Delbridge AR, Grabow S, Strasser A, et al. Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. Nat Rev Cancer. 2016;16:99–109.
   PubMed Web of Science ®Google Scholar